Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.
about
CD200-expressing human basal cell carcinoma cells initiate tumor growthCancer stem cells and immunoresistance: clinical implications and solutionsCD200 expression in human cultured bone marrow mesenchymal stem cells is induced by pro-osteogenic and pro-inflammatory cuesHigh aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cellsCD200 positive human mesenchymal stem cells suppress TNF-alpha secretion from CD200 receptor positive macrophage-like cells.ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemiaInhibitory receptors as targets for cancer immunotherapyCD200: association with cancer stem cell features and response to chemoradiation in head and neck squamous cell carcinoma.Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.Over-Expression of CD200 Predicts Poor Prognosis in Cutaneous Squamous Cell CarcinomaProwling wolves in sheep's clothing: the search for tumor stem cells.Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling.Novel strategies for improved cancer vaccines.Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia.The regulation of the CNS innate immune response is vital for the restoration of tissue homeostasis (repair) after acute brain injury: a brief review.Cell surface markers in colorectal cancer prognosis.Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapyBreast cancer stem cells and the immune system: promotion, evasion and therapy.Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape?Addressing the Inflammatory Response to Clinically Relevant Polymers by Manipulating the Host Response Using ITIM Domain-Containing Receptors.A comparison of serum miRNAs influencing metastatic growth of EMT6 vs 4THM tumor cells in wild-type and CD200R1KO mice.Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice.Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cellsDownstream of tyrosine kinase 1 and 2 play opposing roles in CD200 receptor signaling.Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck.Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes.A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.Immune suppression and evasion in patients with head and neck cancerCD200 facilitates the isolation of corneal epithelial cells derived from human pluripotent stem cells
P2860
Q24630272-3143C3C5-38E5-41AB-8262-CC8F37A273B5Q26769757-8AB3B82C-FF69-4AFC-9722-590269DCE4EBQ28818511-4422E5AA-05DB-4ED1-8795-775D2E2522ADQ33919540-FFA54653-1005-4989-B820-EE76FB9C3FB2Q34171231-20AB1020-8F72-4308-96AA-84DA55FFCE57Q34252280-134FB1F6-D7FC-4F45-BF45-21CFEF22EFC9Q34977414-0EAB660C-5C88-4299-B7CA-77DEAD3F26E7Q35995373-EE6396A6-0514-43D0-9BF1-ADC3DC218DA8Q36019782-6AD9C2FB-366E-43DA-9638-2654687BE7BAQ36557537-39786BE3-1E5D-4325-A55F-7AE8BB7DE04EQ36771508-398C8905-51F2-4B26-A9EF-DDA896EA0B13Q37216610-5B308749-2E16-42FA-A2B0-DB4B575349A7Q37321696-6F1F9042-C45E-4962-BF37-695A34EB7637Q37461365-208CB7E0-355D-4DAB-B5AD-E8CDD0F7F1ECQ37666618-E24DB241-893C-4DDA-A2A1-4DC362E49902Q37678076-05FD241A-8CE6-4A9A-8410-FCB65F99974CQ37820180-43AC32B4-958C-4CFE-9D48-BD49313A0FE5Q37845669-F1883D6F-2F5E-437D-84F5-CE2F4DFCD6F2Q37955957-7CAC68B4-EFA2-4C95-B05D-E32F2065482FQ38226597-E77B56C3-3787-4C85-9052-93940C21A5A6Q38239661-AEADDA74-E4FE-410F-82BD-EFE3A9FD2AFFQ38364218-DD22F14B-3668-4DB2-959C-5D106CC18E3EQ38433475-9D907E4B-80F2-4E46-A29F-892FBB6B58ADQ39313794-E5F225BE-4D6E-431C-892E-68D082EED073Q39619069-DAF732E0-7FE9-433C-8413-183B4995A018Q39794185-0141F707-6E81-44F1-AD10-289FE912082EQ41109622-FD1D53C5-F267-40C2-88EA-535721909A8FQ42320974-C2912795-B3D3-4F05-ADAB-4AF072B8099AQ42509521-B5271CFF-82B9-446D-8622-519A24243484Q47637581-AD78FD6B-DA59-4D8D-81AA-C9543B42BD0FQ58289735-980F8357-739B-4A2A-BB00-246C88D78328Q58589538-35CCDC2F-D701-4B1E-B076-009EBF4B74BB
P2860
Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.
@ast
Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.
@en
type
label
Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.
@ast
Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.
@en
prefLabel
Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.
@ast
Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.
@en
P2093
P2860
P1476
Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.
@en
P2093
Brian T Kawasaki
Elaine M Hurt
Madhuri Kalathur
Tashan Mistree
William L Farrar
P2860
P304
P356
10.1016/J.BBRC.2007.10.067
P407
P577
2007-10-25T00:00:00Z